25 Feb 2026 ORPOF OSE (PNK) $11.60 market: oversold bounce entry
ORPOF stock trades at $11.60 on 25 Feb 2026 during U.S. market hours, marking a low-volume setup for an oversold bounce. The PNK-listed OSE Immunotherapeutics (United States, USD) shows a thin float with volume 748 and avgVolume 611, which can amplify short-term swings. Investors using an oversold bounce strategy should weigh the biotech pathway milestones, upcoming earnings date 2026-03-26, and current valuation metrics before entering.
ORPOF stock: Key snapshot and session context
ORPOF stock closed at $11.60 with no intraday change on low activity. Market cap stands at $260,251,893, shares outstanding 22,435,508, EPS -0.98, and PE -11.86. The listing is on PNK and trading currency is USD. These raw figures show a compact market structure that can fuel volatile short-term moves during market hours.
ORPOF stock: Technical setup for an oversold bounce
Price sits at the 50-day and 200-day averages, both $11.60, which creates a neutral moving average backdrop. Relative volume is 1.22, suggesting slightly elevated attention versus the average. Low absolute volume means a modest buy flow could push price higher quickly. Traders should watch a breakout above $12.50 for confirmation of a short-term bounce and use a tight stop under $10.40 to limit downside.
ORPOF stock: Fundamental metrics and catalysts
OSE Immunotherapeutics focuses on immuno-oncology and autoimmune therapies, including Phase III asset Tedopi and several early-stage programs. The next earnings announcement is scheduled for 2026-03-26, which is a near-term catalyst. Cash runway and partnership updates, especially collaborations with Boehringer Ingelheim and Servier, will drive fundamental re-rating. Current losses and negative EPS reflect development-stage biotech risk.
ORPOF stock: Meyka AI grade and forecast
Meyka AI rates ORPOF with a score out of 100: 63.78 (B, HOLD). This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects $11.60, matching the current price $11.60 and implying 0.00% near-term upside. Forecasts are model-based projections and not guarantees.
ORPOF stock: Risk profile and event timeline
Key risks include trial results, regulatory readouts, and low trading liquidity that can widen spreads. The company reports earnings on 2026-03-26, creating binary risk. Sector moves in Biotechnology and Healthcare may amplify ORPOF stock moves. Monitor headline risk from partnerships and clinical updates as they can produce sharp price gaps.
ORPOF stock: Practical trading plan for an oversold bounce
For the oversold bounce strategy, scale entry into size after a confirmed intraday reversal and volume above 1,200 shares. Set a conservative price target near $12.50 and a stop loss at $10.40. Consider partial profit taking at $13.80 and hold a smaller tranche to a bull target of $16.00 if clinical news turns positive.
Final Thoughts
ORPOF stock presents a clear short-term oversold bounce setup at $11.60 on 25 Feb 2026 during market hours. The company’s biotech pipeline and a scheduled earnings date on 2026-03-26 create near-term catalysts. Meyka AI’s forecast model projects $11.60, implying 0.00% immediate upside versus the current price. Our technical plan uses conservative targets: downside support at $9.00 (implied -22.41%), a base target at $12.50 (implied +7.76%), and a bull target at $16.00 (implied +37.93%). These targets reflect a balanced view of trial risk, low liquidity, and partnership potential. Remember, Meyka AI grades and forecasts support analysis but are model projections and not guarantees. Traders using an oversold bounce approach should size positions for volatility and keep stops tight around the $10.40 level.
FAQs
What is the current price and session status of ORPOF stock?
ORPOF stock trades at $11.60 during market hours on 25 Feb 2026, with volume 748 and an average volume of 611, indicating light trading activity.
How does Meyka AI rate ORPOF stock and what does it mean?
Meyka AI rates ORPOF with a score out of 100 at 63.78 (B, HOLD). The grade considers benchmark and sector comparisons, growth, key metrics, and analyst signals. It is informational, not investment advice.
What are realistic price targets for ORPOF stock?
Conservative target $9.00 (implied -22.41%), base target $12.50 (implied +7.76%), bull target $16.00 (implied +37.93%). Targets assume varying clinical or partnership outcomes.
What short-term trading setup suits ORPOF stock?
An oversold bounce setup works: look for reversal volume, entry on weakness with a stop under $10.40, and partial profit taking near $13.80 to manage binary biotech risk.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.